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Background: In the present study we determined the relative contribution of two processes to breast cancer
progression: (1) Intrinsic events, such as activation of the Ras pathway and down-regulation of p53; (2) The
inflammatory cytokines TNFα and IL-1β, shown in our published studies to be highly expressed in tumors of >80%
of breast cancer patients with recurrent disease.
Methods: Using MCF-7 human breast tumor cells originally expressing WT-Ras and WT-p53, we determined the
impact of the above-mentioned elements and cooperativity between them on the expression of CXCL8 (ELISA,
qRT-PCR), a member of a “cancer-related chemokine cluster” that we have previously identified. Then, we
determined the mechanisms involved (Ras-binding-domain assays, Western blot, luciferase), and tested the impact
of Ras + TNFα on angiogenicity (chorioallantoic membrane assays) and on tumor growth at the mammary fat pad
of mice and on metastasis, in vivo.
Results: Using RasG12V that recapitulates multiple stimulations induced by receptor tyrosine kinases, we found that
RasG12V alone induced CXCL8 expression at the mRNA and protein levels, whereas down-regulation of p53 did not.
TNFα and IL-1β potently induced CXCL8 expression and synergized with RasG12V, together leading to amplified
CXCL8 expression. Testing the impact of WT-Ras, which is the common form in breast cancer patients, we found
that WT-Ras was not active in promoting CXCL8; however, TNFα has induced the activation of WT-Ras: joining these
two elements has led to cooperative induction of CXCL8 expression, via the activation of MEK, NF-κB and AP-1.
Importantly, TNFα has led to increased expression of WT-Ras in an active GTP-bound form, with properties similar to
those of RasG12V. Jointly, TNFα + Ras activities have given rise to increased angiogenesis and to elevated tumor cell
dissemination to lymph nodes.
Conclusions: TNFα cooperates with Ras in promoting the metastatic phenotype of MCF-7 breast tumor cells,
and turns WT-Ras into a tumor-supporting entity. Thus, in breast cancer patients the cytokine may rescue the
pro-cancerous potential of WT-Ras, and together these two elements may lead to a more aggressive disease. These
findings have clinical relevance, suggesting that we need to consider new therapeutic regimens that inhibit Ras
and TNFα, in breast cancer patients.
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Recent studies have shown that sequential genetic/epi-
genetic alterations in intrinsic cellular components and
the interactions between the tumor cells and their intim-
ate microenvironment play major roles in the regulation
of malignancy. The genetic/epigenetic modifications in
intrinsic cellular components endow the tumor cells
with the ability to circumvent normal regulatory pro-
cesses. Well-defined alterations include the constitutive
activation of Ras (e.g., RasG12V) and the down-regulation
of the tumor-suppressive activity of p53, which may
be accompanied by oncogenic gain-of-function activity
[1-4]. Interactions between tumor cells and their intim-
ate microenvironment improve the abilities of those cells
to propagate and metastasize. Here, major roles were re-
cently identified to inflammatory cells and soluble in-
flammatory mediators that are present in the tumor
microenvironment [4-8].
In a previously published study, we demonstrated the
effects of these alterations and interactions on the ability
of non-transformed cells to acquire a pro-malignancy
phenotype, demonstrated by elevated expression of a
“cancer-related chemokine cluster” [9]. This cluster in-
cluded the highly angiogenic, malignancy-promoting
chemokine CXCL8, as well as the tumor-promoting
chemokine CCL2 [8,10-14]. We showed that the in-
flammatory cytokines tumor necrosis factor α (TNFα)
and interleukin 1β (IL-1β), which have recently been
suggested to promote malignancy [15-20], had a stron-
ger effect on the malignancy phenotype of these cells
than alterations in intrinsic cellular components did.
We also found that RasG12V could not induce the che-
mokine cluster in the absence of cooperation with
down-regulated p53 activities (e.g., down-regulation by
shRNA) [9].
The relative roles played by intrinsic and microenvi-
ronmental factors may vary over the course of the
malignancy process. Currently, information on the
equilibrium between these two sets of factors in cancer
and their ability to cooperate in dictating the angio-
genic and malignancy phenotypes of tumor cells is
relatively limited. In the present study, we used a well-
defined cell system of human breast tumor cells (see
below) to examine the interactions between these fac-
tors. We determined the effects of these factors on
CXCL8 expression, using CXCL8 as a proxy for many
pro-tumorigenic factors that may be induced in tumor
cells. Then, we identified the joint effects of the intrin-
sic and inflammatory elements on angiogenesis, tumor
growth and metastasis.
The inflammatory microenvironment was represented
in our current study by TNFα and IL-1β. These cyto-
kines are extensively expressed in the tumor cells of
more than 80% of breast cancer patients with relapseddisease [21] and they have recently been identified as
tumor-promoting entities (e.g., [15-26]). While having
cytotoxic effects when acutely administered to tumors,
the chronic presence of TNFα in breast tumor sites leads
to increased tumor aggressiveness; IL-1β up-regulates
processes that contribute to higher angiogenesis, tumor
growth and progression in breast cancer (e.g., [21-26]).
In parallel, we examined the Ras and p53 pathways. Ras
has been shown to be hyper-activated in breast cancer
patients due to excessive stimulation of receptor tyrosine
kinases (RTKs), such as ErbB2, which is amplified in
approximately 25% of the patients. Also, in about
25% of breast cancer patients, p53 is down-regulated
[1,3,27-30]. Supporting our choice of TNFα and IL-1β,
and of Ras and p53, are studies suggesting that these ele-
ments may be involved in the regulation of inflammatory
chemokines in cancer ([21,31-34] and [35-39]).
In this study, we demonstrated that RasG12V, which is
the form of Ras that recapitulates the activation of Ras
by multiple RTKs (as is the case in breast cancer), in-
duced the release of CXCL8 and CCL2 from MCF-7 hu-
man breast tumor cells, without any need to cooperate
with the down-regulation of p53. Moreover, in these
cells TNFα and IL-1β cooperated with RasG12V to pro-
mote the expression of CXCL8 at the mRNA and protein
levels. In parallel, we found that wild-type Ras (WT-Ras)
has cooperated with TNFα, and these two elements to-
gether gave rise to the amplified expression and release
of CXCL8 by the tumor cells. Also, signals delivered by
TNFα increased the overall levels of the activated, GTP-
bound form of WT-Ras, which then induced the up-
regulation of CXCL8 expression through MEK, NF-κB
and AP-1. Moreover, the joint activities of TNFα and ac-
tivated Ras led to cooperative induction of angiogenesis
and to increased dissemination of tumor cells to lymph
nodes (LN).
The results obtained in our study propose that interac-
tions between inflammatory factors and oncogenic path-
ways aggravate disease course in breast cancer, and are
supported by several recent findings in the field [40,41].
If generalized through investigation in other suitable
breast tumor systems, such mechanisms imply that in
breast cancer patients whose tumors contain high levels
of the inflammatory cytokine TNFα and whose cancer
cells generally do not carry mutations in Ras, TNFα may
activate WT-Ras towards a pro-cancerous phenotype that
leads to devastating tumor-promoting outcomes. These
results may have important clinical implications as they
suggest that the use of inhibitors of mutated and thus
hyper-activated Ras (such inhibitors are now in clinical
trials, [2]) as well as inhibitors of TNFα (currently in use
for the clinical treatment of autoimmune diseases [6])
may be considered in patients whose tumor cells do not
carry any intrinsic Ras mutation, but do express high
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possibly in other malignancies as well.
Methods
Cells, vectors and transfections
The study was performed with MCF-7 cells, which are
human luminal breast tumor cells that (1) Express WT-
Ras [29,30]; (2) Express WT-p53 [30,42]; (3) Respond to
TNFα and to IL-1β [21,32,43]. This cell line has pro-
vided the unique setup required for our study, as also
described in the “Results” section. The cells were kindly
given to us by Prof. Kaye (Weizmann Institute of Sci-
ence, Rehovot, Israel) and were maintained in growth
media containing DMEM supplemented by 10% fetal
calf serum (FCS), 2 mM L-glutamine, 100 Units/ml
penicillin, 100 μg/ml streptomycin and 250 ng/ml
amphotericin (all from Biological Industries, Beit Hae-
mek, Israel). The cells were authenticated on the basis of
published characteristics of MCF-7 cells ([44] and
reviewed in [45]) by verifying that they express an active
estrogen receptor α, respond to estrogen, express low
expression of ErbB2, form tumors upon supplementation
of estrogen and matrigel and have low metastatic poten-
tial. In line with published reports on TNFα-induced
cytolysis of MCF-7 cells, TNFα has induced cytolysis
in ~15-30% of Ras-expressing cells.
MCF-7 cells were stably transfected by electroporation
(using MP-100 MicroPorator, Digital Bio, Seoul, Korea;
Transfection was performed according to manufacturer’s
instructions) to express a well-recognized shRNA to p53
(on p-super-retro; Kindly provided by Prof. Agami,
Netherlands Cancer Institute, Amsterdam, Netherlands)
or the control vector. Following selection with 6 μg/ml
puromycin (A.G. Scientific, San Diego, CA), the cell
population was used as a whole in order to prevent bias
towards specific cell clones, and p53 down-regulation
was verified by Western blot (WB) (see “Results”). In
parallel, MCF-7 cells were transiently transfected by
electroporation (as described above) with GFP-H-
RasG12V (=RasG12V) or by control GFP-expressing vector
(pEGFP-N3). The whole population of transfected cells
was used, and Ras over-expression was verified by GFP
expression (see “Results”). The activation of RasG12V was
validated by Ras-binding-domain assays (see “Results”)
and by elevated Erk phosphorylation levels (data not
shown). Overall, the following 4 cell types were estab-
lished and used in the in vitro experiments: p53shRNA,
RasG12V, RasG12V + p53shRNA and control cells (express-
ing control vectors for both types of transfection). For
use in other in vitro experiments, cells transiently ex-
pressing GFP-H-WT-Ras (=WT-Ras) have been gener-
ated (all procedures were performed as detailed above
for GFP-H-RasG12V). For in vivo experiments, MCF-7
cells were infected to express H-RasG12V or controlvector (p-Babe). Then, stable cells were selected by 50
μg/ml hygromycin and RasG12V over-expression was
verified by quantitative real-time polymerase chain reac-
tion (qRT-PCR; Data not shown).
Also, transient transfections with ErbB2 were performed
(vector kindly provided by Prof. Pinkas-Kramarski, Tel
Aviv University, Tel Aviv, Israel). ErbB2 over-expression
was verified by qRT-PCR (see “Results”), and the whole
population of transiently-transfected cells was used.
In specific experiments, a pool of 4 siRNAs to p65
(Cat # MU-003533-02; Dharmacon, Lafayette, CO, USA)
or control siRNA (Dharmacon) were introduced to the
cells by ICAFectin (Cat. # ICA441; In-Cell-Art, Nantes,
France, following manufacturer’s instructions), together
with WT-Ras. After this step (that by definition cannot
be followed by selection), the cell population was used
as a whole, and effective p65 down-regulation was veri-
fied by WB (see “Results”).
ELISA assays and qRT-PCR analyses
Following transfection with vectors coding for RasG12V,
WT-Ras, p53shRNA or with control vectors, MCF-7 cells
were grown in serum-free medium. Based on titration
analyses, the cells were stimulated with TNFα or IL-1β
at selected concentrations, which agree with the con-
ventional concentration range used in other research
systems: recombinant human (rh) TNFα at 50 ng/ml
(Cat. # 300-01A; PeproTech, Rocky Hill, NJ, USA), rhIL-
1β at 500 pg/ml (Cat. # 200-01B; PeproTech), or their
solubilizer (0.1% BSA). Chemokine secretion and mRNA
levels were determined by ELISA and qPCR analyses
(Figures 1,2,3,4).
For ELISA assays, the cells were grown in serum-free
medium for 24 hr without or with cytokine stimulation.
Then, CXCL8 and CCL2 levels were determined by
ELISA in conditioned medium (CM), using standard
curves with rhCXCL8 or rhCCL2 (Cat. # 200-08 or #
300-04, respectively; PeproTech), at the linear range
of absorbance. The following antibodies were used (all
from PeproTech): For CXCL8 - coating monoclonal an-
tibodies (Cat. # 500-P28), detecting biotinylated rabbit
polyclonal antibodies (Cat. # 500-P28Bt); For CCL2 -
coating monoclonal antibodies (Cat. # 500-M71), de-
tecting biotinylated rabbit polyclonal antibodies (Cat. #
500-P34Bt). Then, streptavidin-horseradish peroxidase
(HRP; Jackson ImmunoResearch Laboratories, West
Grove, PA) and the substrate TMB/E solution (Chemicon,
Temecula, CA, USA) were added. The reaction was
stopped by the addition of 0.18 M H2SO4 and was mea-
sured at 450 nm.
In general, chemokine mRNA levels were determined
by qRT-PCR at the termination of the experiment,
when CM were collected for ELISA. In specific cases
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Figure 1 RasG12V induces CXCL8 expression independently of deregulated p53, and synergizes with the inflammatory cytokines TNFα
and IL-1β. MCF-7 cells were transfected to express p53shRNA, RasG12V, RasG12V + p53shRNA or the appropriate control vectors. (A, B) Induction of
CXCL8 by RasG12V ± p53shRNA expression, determined in cell CM at the protein level by ELISA (A), or at the mRNA level by qRT-PCR (B). (C, D)
Induction of CXCL8 expression by the synergistic activities of RasG12V with IL-1β (500 pg/ml) or TNFα (50 ng/ml), determined at the protein level
by ELISA (C), and at the mRNA level by qRT-PCR (D). Cytokine concentrations were selected based on previous titration analyses. *p < 0.05,
**p < 0.01, ***p < 0.001 compared to control transfectants (A, B), or to non-stimulated cells (C, D). NS = Not significant. In all panels, a
representative experiment of n≥3 is presented. Please see “Methods” for additional details on times of CM collection, and of mRNA analyses.
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lyses. Total RNA was isolated from the cells using the
EZ-RNA kit (Biological Industries), and first-strand
cDNA was produced using the M-MLV reverse tran-
scriptase (Ambion, NY, USA). Quantification of cDNA
targets by qRT-PCR was performed on Rotor Gene 6000
(Corbett Life Science, Sydney, Australia), using Rotor
Gene 6000 series software. Transcripts were detected
using SYBR Green I (Thermo Fisher Scientific, Waltham,
MA, USA) according to the manufacturer’s instructions.
The primers were as follows: For CXCL8 (Genbank acces-
sion no. NM_000584): forward 5′-TTCTGCAGCTCTGT
GTGAAG-3′, reverse 5′-CAGTGTGGTCCACTCTCA
AT-3′; For CCL2 (Genbank accession no. NM_002982):
forward 5′-TCGCTCAGCCAGATGCAATC-3′, reverse
5′-CCTTGGCCACAATGGTCTTG-3′; For ErbB2 (Gen-
bank accession no. NM_001005862): forward 5′-GAAAC
CTGACCTCTCCTACATG-3′, reverse 5′-TTGTCATCC
AGGTCCACACA-3′; For the normalizing gene rS9 (Gen-
bank accession no. NM_001013): forward 5′-TTACA
TCCTGGGCCTGAAGAT-3′ and reverse 5′-GGGATGTTCACCACCTGCTT-3′. PCR amplification was per-
formed over 40 cycles (95°C for 15 seconds, 59°C for 20
seconds, 72°C for 15 seconds). Dissociation curves for
each primer set indicated a single product, and no-
template controls were negative after 40 cycles. Quantifi-
cation was performed by standard curves, on the linear
range of quantification.
When indicated, the pharmacological inhibitor of
MEK, PD98059 (Cat. # 9900; Cell signaling Technology,
Danvers, MA, USA), was used in a conventional concen-
tration of 50 μM. The inhibitor was added to cell cul-
tures 2 hr prior stimulation of the cells by TNFα, and
was present in culture throughout the duration of stimu-
lation. Control cells were treated with the solubilizer of
the drug at similar dilution (Dimethyl sulfoxide, DMSO;
Sigma, Saint Louis, MO).
Determination of GTP-Ras levels by Ras-binding-
domain assays
Cells grown in serum-free medium were stimulated by


















































































































































Figure 2 TNFα and WT-Ras cooperate in inducing CXCL8 up-regulation. (A) Induction of CXCL8 at the mRNA level, determined by qRT-PCR
in MCF-7 cells transfected to over-express ErbB2 or control vector, and stimulated by EGF (30 ng/ml). (B) Induction of CXCL8 at the protein level,
determined by ELISA in CM of MCF-7 cells transfected to express RasG12V, WT-Ras or the appropriate control vector. (C, D) CXCL8 induction in
MCF-7 cells transfected to express WT-Ras and stimulated by TNFα (50 ng/ml), determined at the protein level in cell CM by ELISA (C) and at the
mRNA level by qRT-PCR (D). *p < 0.05, **p < 0.01, ***p < 0.001 compared to control transfectants (A, B), or to non-stimulated cells (C, D). 1, Not in
all assays this value was significant. NS = Not significant. In all panels, a representative experiment of n≥3 is presented. Please see “Methods” for
additional details on times of CM collection, and of mRNA analyses.
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Cell lysates were used in two parallel procedures
(Figure 3): (1) GTP-Ras levels were determined by the
glutathione S-transferase-Ras-binding-domain of Raf (RBD)
pull-down assay as previously described [46], followed by
determination of activated Ras levels by pan-anti-Ras anti-
bodies (Cat. # OP40; Calbiochem, Gibbstown, NJ, USA)
using WB. (2) Equivalent total lysates were used to deter-
mine total Ras levels (antibody as above) and β-tubulin
(Cat. # AK-15; Sigma) by WB.
WB analyses
Cells grown in serum-free medium were stimulated by
TNFα (50 ng/ml) for 5 and 10 min in studies of Erk
phosphorylation, for 10 min in NF-κB stimulation or for
30 min in c-Jun activation (based on kinetics analyses).
To detect decrease in IκBα - the NF-κB inhibitor whose
degradation allows for p65 activation - the levels of IκBα
were determined following 24 hr of stimulation by TNFα
(based on previous kinetics analyses).Following stimulation, cells were lysed in RIPA lysis buf-
fer. Lysis was followed by conventional WB procedures.
Antibodies against the following proteins were used: phos-
phorylated Erk (Cat. # M9692; Sigma); Erk (Cat. # M5670;
Sigma), p53 (From DO-1 hybridoma, kindly provided by
Prof. Sara Lavi, Tel Aviv University, Tel Aviv, Israel); phos-
phorylated p65 (Cat. # 3033; Cell Signaling Technology);
total p65 (Cat. # 4764; Cell Signaling Technology); IκBα
(Cat. # 4814; Cell Signaling Technology); GAPDH (Cat. #
ab9485; Abcam, Cambridge, UK). Phosphorylated c-Jun
was immunoprecipitated and detected by antibodies tar-
geting phosphorylated c-Jun (Cat. # 1527-S; Epitomices,
Burlingame, CA, USA); Ras and tubulin antibodies –
please see below in the following sub-section.
After transfer to membranes, HRP-conjugated secondary
antibodies were used, as appropriate: goat anti-mouse-HRP
(Cat. # 115-035-166; Jackson ImmunoResearch Labora-
tories, West Grove, PA, USA) and goat anti-rabbit-HRP
(Cat. # 111-035-003; Jackson ImmunoResearch Labora-
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Figure 3 TNFα stimulation leads to increased expression of active GTP-bound WT-Ras, together giving rise to CXCL8 up-regulation
through the MEK pathway. (A) MCF-7 cells were transfected to express RasG12V, WT-Ras or the appropriate control vector. Cell lysates were used
for RBD pull-down assays, determining the levels of activated GTP-bound Ras, and in parallel for determination of total Ras or β tubulin (loading
control). The figure shows the levels of GTP-bound Ras in WT-Ras-transfected cells, not-stimulated or stimulated by TNFα (50 ng/ml; 7 min or
6 hr) or EGF (100 ng/ml; 3-4 min). The figure also shows that Ras was not detected in cells transfected with the empty control vector. The fast-
migrating band of GTP-bound Ras has been detected by others [49-53], and may represent a post-translationally modified form of the protein.
This band was highly expressed in the RasG12V-expressing tumor cells, and also could be minimally detected in WT-Ras-expressing tumor cells,
albeit only following longer exposure (Additional file 3A). (B, C) MCF-7 cells that were transfected to express WT-Ras were not-stimulated or
stimulated by TNFα (50 ng/ml) in the absence or in the presence of the MEK inhibitor PD98059 (50 μM). (B) CXCL8 mRNA levels were determined
by qRT-PCR. (C) CXCL8 expression levels were determined by dual luciferase assay, using the luciferase gene under the control of WT CXCL8
promoter. Non-stimulated cells were given the value of 1. In panels A-B a representative experiment of n≥3 is presented. Panel C presents the
average ± SD of n=3. *p<0.05, ***p<0.001 compared to non-stimulated cells. In Panel A, the EGF results are representatives of 3 out of 4 stimulations
performed. Please see "Methods" for additional details on the experimental procedures and statistical analyses performed in this part of the study.
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quantitated by densitometry using TINA image analysis
software.
Dual luciferase assays
The assays were performed with firefly luciferase gene
under the control of the following promoters: (1) WT
CXCL8 promoter (Figure 3). (2) Promoter expressing 3
conserved NF-κB binding sites (3X-κB-L, including
MHC NF-κB binding sites), kindly provided by Prof.
Wiemann (DKFZ, Heidelberg, Germany) (Figure 4 and
Table 1). (3) CXCL8 promoter expressing WT or mutated
AP-1 binding site (Table 2). The promoter included the
5′-flanking region from -558 to +98 bp, with WT AP-1
binding site (5′-AAGTGTGATGACTCAGGTTTGCCC
TGA-3′) or AP-1-mutated binding site (5′-AAGTGTGATATCTCAGGTTTGCCCTGA-3′). Both constructs were
kindly provided by Prof. Muhl (University Hospital
Goethe-University, Frankfurt, Germany). In each case, a
construct coding for renilla luciferase was used for
normalization of the results according to transfection
yields (kindly provided by Dr. Zor, Tel Aviv University, Tel
Aviv, Israel).
In luciferase assays, all relevant vectors (including
WT-Ras) were transiently transfected to MCF-7 cells by
ICA Fectin. After 24 hr, the cells were stimulated by
TNFα for 8 hours in serum-free medium (on the basis
of preliminary kinetics studies) to allow for promoter ac-
tivation, and were processed with the reagents provided
in the Dual-Luciferase Assay System Kit (Cat. # E1019;
Promega, Madison, WI, USA). Luciferase activity
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Figure 4 (See legend on next page.)
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Figure 4 TNFα +WT-Ras up-regulate CXCL8 expression via the activation of NF-κB and induce AP-1 stimulation. MCF-7 cells were
transfected with WT-Ras vector or with control vector, and were not-stimulated or stimulated by TNFα (50 ng/ml). (A) p65 phosphorylation was
determined by WB. Control vector-transfected non-stimulated cells were given the value of 1. (B) NF-κB activation was determined in cells
transfected to express the luciferase gene under the control of 3 conserved repeats of NF-κB binding sites, using dual luciferase assay. Control
vector-transfected non-stimulated cells were given the value of 1. The results obtained in each of the 3 repeats are presented in Table 1.
(C) WT-Ras-expressing cells were transfected with a pool of 4 siRNAs targeting p65 (25-35 nM), or with appropriate control siRNA. CXCL8 protein
expression levels were determined in cell CM by ELISA. (D) c-Jun phosphorylation was determined by WB, following c-Jun immunoprecipitation.
GAPDH was used for determination of protein amounts in original cell lysates, prior to immunoprecipitation. Control vector-transfected non-
stimulated cells were given the value of 1. The direct roles of AP-1 in mediating the TNFα +WT-Ras stimulation of CXCL8 are presented in Table 2.
In panels A and D a representative experiment of n≥3 is presented. Each of the results presented in Panels B and C show the average ± SD of
n=3. *p < 0.05, ***p < 0.001 compared to non-stimulated cells. Please see “Methods” for additional details on the experimental procedures and
statistical analyses performed in this part of the study.
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hibitor PD98059 was used, under the same conditions de-
scribed above.
Chick chorioallantoic membrane (CAM) assay
For assessment of neo-vascularization, WT-Ras over‐
expressing cells were stimulated by TNFα (50 ng/ml)
in serum‐free medium, while vector-expressing control
cells were not treated with TNFα. After 24 hr (allowing
for accumulation of angiogenic factors), CM were col-
lected and used in CAM assays (Figure 5). To this end,
25 mm2 gelatin patches were soaked in the CM for 4
hr, and then implanted on the top of the growing CAM
on embryonic day 3 of development. Patches were re-
placed on a daily basis for the following 3 days of the
experiment. On embryonic day 6, angiogenesis intensity
was determined on the basis of length, thickness and
sprouting of the embryo vessels, combined. Angiogen-
esis was evaluated independently by 3 researchers in an
unbiased manner. Pictures were taken using a camera
set on a binocular.
Flow cytometry
Transfection yields of GFP-RasG12V and GFP-WT-Ras
were determined by flow cytometry, using a BectonTable 1 The cooperativity of WT-Ras and TNFα stimulates
the transcriptional activity of NF-κB
Control cells WT-Ras cells
– TNFα – TNFα
Exp #1 1.00 2.64 1.62 3.39
Exp #2 1.00 2.94 3.29 4.64
Exp #3 1.00 2.78 1.98 4.60
MCF-7 cells were transfected with WT-Ras vector or with control vector, and
were not-stimulated or stimulated by TNFα (50 ng/ml). Stimulation of the
transcriptional activity of NF-κB was determined in cells transfected to express
the luciferase gene under the control of 3 conserved repeats of NF-κB binding
sites, using dual luciferase assay. Control vector-transfected non-stimulated
cells were given the value of 1. The table presents the results obtained in 3
independent experiments, whose average results are shown in Figure 4B.
Please see “Methods” for additional details on the experimental procedures
performed in this part of the study.Dickinson FACSort (Mountain View, CA, USA). Base-
line staining was obtained by using untransfected cells.
Staining patterns were determined using the win MDI
software.
Tumor growth and metastasis
In these assays we used MCF-7 cells that were infected
to stably express RasG12V, or cells infected by control
vector (previously described in “Cells, vectors and trans-
fections”). Then, these cells were infected to stably ex-
press mCherry (by pQC-mCherry retroviral vector).
mCherry + RasG12V -expressing cells, or mCherry-control
cells, were either not-stimulated or stimulated by TNFα
(50 ng/ml) for 8 hr, then the medium was exchanged
to a serum-deprived medium, without TNFα. After ad-
ditional 16 hr that allowed TNFα-induced intracellular
processes to take place, the cells were inoculated to the
mammary fat pad of female nude mice, as described in
Figure 3A.
Ten days prior to tumor cell injection to female nude
mice, the mice were implanted sub-cutaneously with
slow-release estrogen pellets (1.7 mg/pellet, 60 days
slow release, SE-121; Innovative Research of America,
Sarasota, FL, USA). The different mCherry-expressing
tumor cells (4×106/mouse) were supplemented with
matrigel (Cat. # 356234; BD Biosciences, Franklin Lakes,
NJ, USA) and CM that were mixed in 1:1 volume (see
Figure 6A for details). The cells were injected to the
mammary fat pad of mice, and once a week the mice were
injected intra-tumor with 150 μl CM (concentrated
~×12), obtained from control cells or TNFα-stimulated
RasG12V -expressing cells, as described in Figure 6A.
Tumor progression and LN metastases were moni-
tored weekly by CRI™ Maestro non-invasive intravital
imaging system in intact mice. At the termination of the
experiments (see legend to Figure 6B), tumors were ex-
cised and their size was analyzed by the Maestro device.
Due to depth of the lung tissue, mCherry signals in the
lungs were not well detected by the Maestro device
when intact mice were analyzed. Therefore, kinetics of
lung metastases were not followed in the study. The
Table 2 TNFα +WT-Ras up-regulate CXCL8 expression via the activation of AP-1
Control cells WT-Ras cells
WT CXCL8 promoter AP-1 mutated CXCL8 promoter WT CXCL8 promoter AP-1 mutated CXCL8 promoter
– TNFα – TNFα – TNFα – TNFα
Exp #1 1.00 1.56 0.03 0.12 0.72 2.42 0.05 0.14
Exp #2 1.00 5.40 0.10 0.42 1.79 6.11 0.12 0.48
Exp #3 1.00 3.33 0.11 0.30 1.05 4.94 0.07 0.16
MCF-7 cells were transfected with WT-Ras vector or with control vector, and were not-stimulated or stimulated by TNFα (50 ng/ml). Stimulation of the transcriptional
activity of AP-1 was determined in cells transfected to express the luciferase gene under the control of WT AP-1, or mutated AP-1 binding sites in the CXCL8 promoter,
using dual luciferase assay. Control vector-transfected non-stimulated cells were given the value of 1. The table presents the results obtained in 3 independent
experiments. Please see “Methods” for additional details on the experimental procedures performed in this part of the study.
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tee did not allow continuation of the experiments to the
stage of survival analysis. All procedures involving experi-
mental animals were performed in compliance with local



































Figure 5 CM of TNFα-stimulated WT-Ras-expressing cells lead to incre
chorioallantoic membranes (CAM), in which length, thickness and sproutin
of CM were used (see "Results" for details): (1) From non-stimulated contro
(A) A representative CAM image. In each group, n≥5 embryos were tested
angiogenesis intensity was determined by three researchers in an unbiased
embryo vessels, combined. In each of the two independent experiments, n
additional details on times of CM collection.Statistical analyses
Statistical analyses of in vitro experiments were done using
Student’s t tests. Values of p < 0.05 were considered statis-
tically significant, and data were presented as mean ± SD.
In the in vivo studies of primary tumors, statistical2. CM of WT-Ras cells + TNFα
ls
CM of WT-Ras cells
+ TNFα
*
ased angiogenesis. CM of MCF-7 cells were administered on chick
g of embryo vessels were used to determine angiogenicity. Two types
l cells; (2) From WT-Ras-expressing cells, stimulated by TNFα (50 ng/ml).
, in each of 3 independent experiments. (B) In two of the experiments,
manner, using parameters of length, thickness and sprouting of
≥5 embryos were tested in each group. Please see "Methods" for
Figure 6 Cooperativity between TNFα and hyper-activated Ras promotes the dissemination of tumor cells to lymph nodes. The scheme
describes the "Experimental design" of in vivo mouse experiments, including cell preparation. *CM preparation: RasG12V (A) MCF-7 cells were
stimulated by TNFα for 8 hr, CM were removed and replaced by fresh, serum-free non-TNFα-containing medium for additional 36 hr. **CM
preparation: The same as in *, but no TNFα included at any stage. (B) Determination of tumor growth in the mammary fat pad of mice. All MCF-
7 tumor cells expressed mCherry, to enable their detection by the Maestro device in intact mice. To provide accurate determination of tumor
sizes, the Maestro device was used to quantify fluorescence in excised tumors, ex vivo, at the end of two experiments performed (termination of
experiments was based on animal care regulations). The Figure shows combined results of these experiments, including n=7 in each of the mice
groups. For more details on the results in group 4 – see "Results". *p<0.05, **p=0.01, ***p=0.001 for comparisons between the CellsControlCMControl
group and all other groups. (C) Kinetics of tumor cell dissemination to LN, followed by the Maestro device in intact mice in three independent
experiments combined, including a total of n=10-12 in each of the mice groups. All tumor cells expressed mCherry, to enable their detection by
the Maestro device in intact mice, p values are shown in the Figure. No statistical differences were obtained in comparisons between any of the
other Cell-CM combinations.
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and values of p < 0.05 were considered statistically signifi-
cant. The data were presented as mean ± SEM. Analyses of
kinetics of metastasis-free mice were done using Kaplan-Meier’s method, and comparison between groups was
tested by log-rank test. Values of p < 0.05 were con-
sidered statistically significant. Adjustment for multiplicity
of comparisons was done using the Benjamini-Hochberg
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that were presented in the manuscript remained statisti-
cally significant after correcting for their multiplicity [ex-
cept for Figure 1B and Figure 6B (comparison between
groups 4 and 1). Also, several of the results in Figure 4B
did not remain statistically significant after the correction
because the intensity of response varied between the dif-
ferent experiments. Therefore, to show the reproducibility
of the results the data were also provided in Table 1].
Data presentation
All the in vitro experiments were repeated at least 3 times
with similar results. The results of most studies were pre-
sented as a representative experiment of such similar
repeats. Alternatively, when more appropriate to the ex-
perimental conditions of the assays (e.g., luciferase tests),
the results were presented as average of at least n=3.
Results
In breast tumor cells, RasG12V induces CXCL8 (and CCL2)
without need for cooperative down-regulation of p53
At the beginning of this study, we asked whether tumor
cells express similar regulatory patterns to those of non-
transformed cells [9], in terms of CXCL8 regulation by
tumor-promoting alterations in Ras and p53. To address
this question we performed the analyses with MCF-7
cells. These cells are human luminal breast tumor cells
like the majority of tumors in breast cancer patients,
they express WT-p53 [30,42], and do not carry muta-
tions in Ras as is the case in most human breast tumors
[1,29,30,47]. These cells also respond to TNFα and IL-
1β, which were introduced in the proceeding stages of
the study. Thus, MCF-7 cells provided an ideal plat-
form to conduct our studies (that could not be recapit-
ulated in other luminal human breast tumor cells
because they did not carry identical properties to those
of MCF-7 cells in terms of p53 expression, Ras and
ErbB2 activation or the expression of relevant signaling
pathways [30,42]).
To address the roles of p53 in CXCL8 regulation,
stable transfectants were produced, in which the tumor-
suppressor p53 was down-regulated by shRNA (p53shRNA;
Additional file 1A). In parallel, the cells have undergone
transient over-expression with the constitutively active
GFP-tagged RasG12V protein (High RasG12V expression
levels were verified as shown in Additional file 1B;
RasG12V activation has been validated by RBD assays that
are described below and by Erk phosphorylation tests
whose data are not shown). By taking this general ap-
proach of Ras hyper-activation, we have recapitulated the
excessive activation of the Ras pathway in breast cancer,
which is induced in patients by multiple RTK ligands such
as epidermal growth factor (EGF) [1,27,28,47,48]. Overall,
the following 4 cell types were established and usedin the in vitro experiments: p53shRNA, RasG12V, RasG12V +
p53shRNA and control cells (expressing the two control
vectors). Of note, to follow on the results described with
RasG12V, in more progressed stages of the study, WT-Ras
was also addressed (see below).
Similarly to the findings obtained in non-transformed
cells [9], RasG12V + p53shRNA had induced the expression
of CXCL8 in breast tumor cells (Figures 1A and B).
However, in contrast to the non-transformed cells [9],
RasG12V was fully active on its own in inducing CXCL8
in the tumor cells, at the protein and mRNA levels
(Figure 1A and B, respectively), while p53shRNA alone
did not induce any change in chemokine expression, and
did not add significantly to CXCL8 up-regulation by
RasG12V (Figure 1A and B).
These data indicate that in the tumor cells, constitu-
tively active RasG12V could act alone to up-regulate the
expression of CXCL8, with no need for cooperativity
with p53 deregulation. Similar findings were obtained
for CCL2 (Additional file 2), another member of the
“cancer-related chemokine cluster” that was addressed
in our previous study of non-transformed cells [9].
These observations contrasted the findings in non-
transformed cells, where RasG12V had to cooperate with
down-regulation of p53 in order to induce CXCL8 and
CCL2 up-regulation [9]. This difference between the
non-transformed and malignant cells may be due to dis-
crepancies in their genetic setup, as will be discussed
further below (“Discussion”).
In breast tumor cells, inflammatory cytokines act in a
cooperative manner with RasG12V, together giving rise
to exacerbated expression of the pro-angiogenic
chemokine CXCL8
The above findings were followed by determination of
the impacts imposed by inflammatory mediators on the
expression of CXCL8. To this end, the tumor cells were
stimulated by TNFα or IL-1β, using selected concentra-
tions based on previous titration analyses. The results of
Figure 1C indicate that stimulation by TNFα or IL-1β
has induced a prominent up-regulation of CXCL8 secre-
tion, and moreover, that both cytokines acted in a sy-
nergistic manner with RasG12V, leading to exacerbated
release of CXCL8 by the cells. The basis for the coopera-
tive activities of RasG12V with the two cytokines was in
increased mRNA levels (Figure 1D; Please note that
up-regulation in CXCL8 mRNA expression in control
non-stimulated RasG12V-expressing cells could not be de-
tected technically under these experimental conditions be-
cause of the very high induction of CXCL8 mRNA in
RasG12V-expressing cells that were stimulated with TNFα
and IL-1β).
Thus, hyper-activated RasG12V cooperated with in-
flammatory factors that were shown to be prevalent
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potentiating the release of the powerful angiogenic and
tumor-promoting chemokine CXCL8 by the tumor
cells. However, in breast tumors, Ras is rarely mutated,
but nonetheless it is continuously activated because
of excessive stimulation of RTKs such as ErbB2
[1,27,28,47,48]. This would mean that in breast tumor
cells that express endogenously WT-Ras, CXCL8 may
be induced by RTK ligands. To see if this is indeed
the case, we have used the ErbB2-EGF axis as a proof
of concept, with ErbB2-over-expressing MCF-7 cells
(Additional file 3A; At the basal level, MCF-7 cells ex-
press relatively low levels of the receptor [45]). In
these cells, EGF stimulation has induced the expres-
sion of CXCL8 (Figure 2A), indicating that activation
of RTKs is a relevant pathway for induction of CXCL8,
which may account for Ras hyper-activation in breast
tumor cells that do not carry mutated Ras.TNFα cooperates with WT-Ras in elevating CXCL8 levels,
and promotes the expression of activated GTP-bound
WT-Ras
Noting that WT-Ras is the form of the protein that is
abundant in most breast tumor cells [1,47], we asked
whether it acts similarly to RasG12V, and if it is able to
act alone to induce CXCL8 up-regulation. To study the
regulatory functions of a protein that is endogenously
expressed in a WT form in the cells, one needs to either
decrease or increase the expression levels of the protein,
and determine the effects of such manipulations on the
issue that is addressed. Because MCF-7 cells express
three different WT isoforms of Ras [29], the down-
regulation approach would require efficient reduction in
the expression of all three Ras variants without perturb-
ing cellular growth, and such a process may be difficult
to achieve. Therefore, we chose an alternative attitude in
which we over-expressed WT-Ras in the cells. This latter
approach, which is conventionally used as the method-
of-choice in many studies of Ras, also enabled us to ad-
equately compare WT-Ras to RasG12V, which has been
studied in the previous parts of this work.
Thus, WT-Ras was over-expressed in the cells (e.g.,
Additional files 3B and C), and CXCL8 expression levels
were determined. Unlike RasG12V, the over-expression of
WT-Ras in the tumor cells did not induce the expression
of CXCL8 (Figure 2B). However, when WT-Ras-expressing
tumor cells were stimulated by TNFα, cooperativity be-
tween the two pathways was obtained. This was indicated
by the fact that CXCL8 was not induced by WT-Ras ex-
pression alone but was highly promoted when WT-Ras ex-
pressing cells were stimulated by TNFα. This elevated
response was evidenced at the protein and mRNA levels
(Figures 2C and D, respectively).These results attest for functional cooperativity be-
tween TNFα and WT-Ras, leading to induction of
CXCL8 expression as was the case when RasG12V was
expressed in the cells. These findings suggest that stimu-
lation by TNFα has led to activation of WT-Ras, which
was not active otherwise. In such a case, TNFα sti-
mulation was expected to lead to increased levels of ac-
tivated WT-Ras, at the molecular level. To test this
possibility, we established the methods for detecting Ras
activation, using RasG12V - which is the constitutively
active form of the protein - as a positive control. To de-
termine the levels of Ras activation, we used RBD pull-
down assays that give rise to GTP-bound Ras, which is
well-established as the activated form of the protein
[1,2,49]. As shown in Additional file 3A, large amounts
of GTP-bound Ras indeed have been observed in cells
expressing our positive control of RasG12V, while no de-
tection of Ras was obtained in control vector-expressing
cells, as expected (Figure 3A). The GFP-tagged GTP-
bound Ras was observed in the expected MW of ~48
kDa, and the fast migrating band of GTP-bound RasG12V
detected in this case may represent a post-translational
modification of Ras which was observed by others in ana-
lyses of H-Ras and of other forms of Ras [49-53] (please
note that in this experiment, the fast migrating band was
detected, albeit in very low levels, also in non-stimulated
WT-Ras-expressing cells. Its detection required longer
film exposure, as shown in Additional file 3C).
When the levels of activated Ras were compared be-
tween RasG12V and WT-Ras, we found that following the
RBD pull-down assays the levels of GTP-bound WT-Ras
were smaller than those of GTP-bound of RasG12V.
These differences between RasG12V and WT-Ras agree
with the fact that RasG12V is the constitutively active
form of the protein and with our previous observations
(Figure 2B), showing that RasG12V induced CXCL8 up-
regulation, while WT-Ras did not (in the absence of
TNFα stimulation).
Then, we determined the impact of TNFα on the ex-
pression levels of activated GTP-bound WT-Ras. We
found that stimulation of WT-Ras-expressing cells with
TNFα for 6 hr has led to up-regulation in the amounts
of activated WT-Ras obtained by the RBD pull-down as-
says (Figure 3A), as was the case also following the acti-
vation of WT-Ras-expressing cells by an EGF control
(stimulatory conditions adhering to previously published
studies of Ras activation by EGF [54-56]; Figure 3A).
Thus, TNFα has induced the activation of WT-Ras, in a
process that was time-dependent (it was not induced by
brief stimulation with TNFα for 7 minutes), suggesting
that the cytokine has induced autocrine mechanisms
leading to up-regulation of activated WT-Ras. Here,
we would like to indicate that endogenous WT-Ras prob-
ably did not account much to the response induced in
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tively small quantities of endogenous WT-Ras, particularly
following RBD pull-down assays in experiments detecting
GTP-bound Ras (Additional file 3D; Endogenous WT-Ras
had the expected MW of 21 kDa), and the protein levels
were different within experiments. However, we found that
WT-Ras over-expression provided a biologically relevant
system because in some of the experiments we could detect
a certain increase in the levels of activated GTP-bound
endogenous WT-Ras after TNFα activation (but their levels
were low relatively to the amounts obtained by the over-
transfected WT-Ras; Because of the low detectability of
endogenous Ras, the relevant data were not shown).
The above findings obtained with TNFα-activated, over-
expressed, WT-Ras indicate that in response to TNFα,
WT-Ras has been activated at the molecular level and has
gained functional properties similar to those of RasG12V.
This was manifested also by the ability of TNFα-activated
WT-Ras to induce increased expression of CXCL8, as did
RasG12V. Supporting a mechanism in which WT-Ras has
been turned into an active entity, and in line with the fact
that the MEK-Erk pathway mediates many of the Ras-
induced activities [1], MEK-dependent pathways were in-
volved in the ability of TNFα to induce CXCL8 expression
in WT-Ras-expressing tumor cells. The inhibition of
the down-stream effects of MEK by the MEK-inhibitor
PD98059 (evidenced by inhibition of Erk1 and Erk2 acti-
vation in Additional file 4), has led to prominent reduction
of CXCL8 expression (at the mRNA level; Figure 3B), and
to potent inhibition in luciferase expression in CXCL8
promoter-luciferase reporter assays (Figure 5C).
Thus, our findings indicate that following TNFα
stimulation, the content of active, GTP-bound WT-Ras
was increased, recapitulating the activation state of
RasG12V and leading to increase in the release of CXCL8,
a highly angiogenic and pro-malignancy factor. These re-
sults indicate that TNFα has turned WT-Ras into an ac-
tivated, tumor-promoting entity.
The synergistic activities of WT-Ras and TNFα on CXCL8
up-regulation are mediated by the NF-κB and AP-1
transcription factors
Throughout this study, we found that CXCL8 up-
regulation took place at the mRNA level (Figures 1B,D and
2D). Therefore, we asked which regulatory elements are
inducing the transcription of CXCL8, thus leading to the
ability of TNFα +WT-Ras to eventually promote CXCL8
secretion. Here, we studied the roles of NF-κB and
AP-1, two transcription factors known to up-regulate
CXCL8 in the immune context, although to different ex-
tents depending on cell type and stimulus [57].
The activation of NF-κB comes into effect following
down-regulation of the IκBα inhibitor and phosphoryl-
ation of p65 (RelA) [58]. Following TNFα stimulation,the phosphorylation of p65 was increased (Figure 4A)
and IκBα levels were reduced (Additional file 5A). These
general assays of NF-κB activation did not reveal coop-
erativity between TNFα and WT-Ras. However, more
direct and sensitive analyses with dual luciferase assays
using the NF-κB-luciferase reporter, demonstrated that
the stimulation of WT-Ras-expressing cells by TNFα has
increased the transcriptional activity of NF-κB (Figure 4B
and Table 1). Also, siRNAs to p65 have down-regulated
p65 expression (Additional file 5B), and in cells stimu-
lated by TNFα have led to almost complete shut-off of
the TNFα +WT-Ras-induced CXCL8 expression (at the
protein level; Figure 4C). These results provide evidence
for direct roles of the NF-κB pathway in mediating the
TNFα +WT-Ras-induced activation of CXCL8.
In parallel, we found that TNFα +WT-Ras induced co-
operative induction of c-Jun phosphorylation (Figure 4D),
which is a major component of the AP-1 transcription
factor. The phosphorylation of c-Jun indicates that there
was a general process of AP-1 activation but it could not
tell us whether the activation of AP-1 by TNFα +WT-
Ras has led directly to up-regulation of CXCL8 expres-
sion. Looking for appropriate manners to determine the
direct roles of AP-1 in induction of CXCL8 upon TNFα
stimulation of WT-Ras-expressing cells, we wished to
use siRNA/shRNA to c-Jun; however, we could not ob-
tain efficient enough down-regulation of c-Jun expres-
sion, being in line with the fact that c-Jun is essential for
cell proliferation [59]. In the absence of a pharmaco-
logical inhibitor with high enough specificity, we used
luciferase reporter assays in which the CXCL8 promoter
expressed WT or mutated AP-1 binding sites. These
tests have shown cooperativity between TNFα and WT-
Ras in inducing luciferase activation (Table 2); in
addition, marked decrease was noted in luciferase levels
when WT-Ras cells were stimulated by TNFα in the
presence of AP-1-mutated promoter, compared to AP-1-
WT promoter (Table 2). Because the promoter was spe-
cifically the one of CXCL8, these results demonstrate
that TNFα cooperates with WT-Ras in inducing AP-1
activation, together leading to an additive up-regulation
in the transcription of CXCL8.
Overall, the results presented in this part of the study
indicate that following activation of WT-Ras-expressing
cells by TNFα, the NF-κB and AP-1 transcription factors
became activated, and led to increased transcription of
the CXCL8 gene, and thereafter to increased release of
the protein by the tumor cells.
The functional implications of Ras hyper-activation + TNFα
stimulation: Elevated angiogenesis and increased breast
tumor cell dissemination to lymph nodes
The results obtained thus far in this study indicate
that the cooperative activities of TNFα with RasG12V
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release of CXCL8 by the tumor cells. Similarly, many
other pro-cancerous factors may be induced in TNFα
+ Ras-stimulated cells. The outcome of such a process,
if taking place in vivo in malignancies with high TNFα
expression - as is the case in breast cancer - may be
high production of pro-tumorigenic factors by the
tumor cells, including angiogenic ones (such as CXCL8
and CCL2).
To examine whether such a general increase in pro-
tumoral and angiogenic factors indeed leads to increased
angiogenesis, we used the in vivo analysis of chorioallan-
toic membrane (CAM) assay. In this test, multiple pa-
rameters of angiogenesis are affected by angiogenic
factors, including length and thickness of blood vessels
and their sprouting. Due to its multi-parametric nature,
to the high content of vessels in the embryo and to em-
bryo heterogeneity, the results of the CAM assay often
show variability between individual samples within the
same group; thus, the CAM assay could clearly define
differences between two extreme conditions (such as
control vs. Ras + TNFα), but its sensitivity could not de-
termine interim effects that may have been obtained by
other combinations that are less effective in inducing an-
giogenic and pro-tumoral factors. To comply with this
limitation, and in line with our interest in determining
the overall effects induced by multiple angiogenic factors
that could have been promoted by the most potent
process of TNFα stimulation of WT-Ras-expressing
cells, we tested CM from the two most relevant stimula-
tory extreme conditions: (1) CM of WT-Ras-expressing
tumor cells that were stimulated by TNFα. (2) CM of
control vector-expressing tumor cells that were not
stimulated by the cytokine. The results indicate that CM
derived from TNFα-stimulated WT-Ras-expressing tu-
mor cells (shown to produce highly elevated levels of
CXCL8; Figure 2C) induced significantly stronger angio-
genic effects compared to control cells (Figure 6).
In parallel, we asked what is the impact of combined
TNFα stimulation and Ras hyper-activation on tumor
growth and metastasis. MCF-7 cells were documented
as cells with relatively low malignancy potential, and
with very weak invasive and metastasizing capacities
[45]. However, published studies by Weinberg and his
colleagues have shown that under specific conditions,
MCF-7 cells that express oncogenic Ras can form metas-
tases [60]. Thus, to allow for metastatic dissemination
in our study, we followed on these observations and
used RasG12V-expressing MCF-7 cells, compared to cells
transfected with control vector. This approach was valid
in our experimental design because of the functional
similarities between RasG12V and TNFα-stimulated-WT-
Ras, in terms of Ras activation (Figure 3A and B) and in-
duction of CXCL8 (Figures 1 and 2).Using these cells as a research platform, we determined
the impact of TNFα stimulation and its cooperativity with
hyper-activated Ras on the malignancy phenotype of
the cells. To this end, two measures were taken (see
“Experimental design”, Figure 6A): (1) RasG12V-express-
ing cells were stimulated by TNFα in vitro before their
inoculation to mice in order to induce intracellular
mechanisms that would eventually give rise to pro-
duction of pro-malignancy factors, including CXCL8
(as has been shown in the previous figures of the study).
Prior to inoculation to mice, the cells were washed and
thus TNFα was removed, in order to prevent a potential
acute necrotic effect of TNFα in vivo (such an effect
may result out of acute exposure to the cytokine, being
in contrast to the chronic and tumor-promoting presence
of TNFα at breast tumor sites along disease course).
(2) To sustain the in vivo effect of joint TNFα + Ras
hyper-activation (RasG12V) in inducing the release of
multiple pro-tumorigenic factors by the tumor cells, we
have introduced a previously described approach [61,62],
in which tumors were inoculated with tumor cell products
throughout the process of tumor growth. Here, eight
hours following stimulation by TNFα, the medium of the
cells was exchanged to TNFα-deficient medium, and fol-
lowing additional 36 hr of cell growth, CM that were
enriched in tumor-promoting factors such as CXCL8
(data not shown) were collected and injected to tumors.
Thus, tumors were inoculated on a weekly basis with CM
derived from TNFα stimulated-RasG12V cells, compared to
CM from control cells. Overall, the analyses included the
4 most relevant groups of mice that could provide in-
sights into the tumor-promoting roles of factors resulting
out of the activation of Ras by TNFα (Figure 6A): (1)
CellsControlCMControl; (2) CellsControlCMRas-G12V+TNFα;
(3) CellsRas-G12V+TNFαCMControl; (4) CellsRas-G12V+TNFα
CMRas-G12V+TNFα.
Comparison of CellsControlCMControl to CellsRas-G12V+TNFα
CMControl (groups 1 vs. 3, Figure 6B) has shown that ex-
pression of RasG12V in the cells (stimulated in vitro by
TNFα prior to their injection to mice), has led to increased
tumor growth. In parallel, CMRas-G12V+TNFα elevated the
ability of CellsControl (cells not expressing RasG12V) to de-
velop primary tumors (groups 2 vs. 1). This latter re-
sult indicates that following their stimulation by TNFα,
RasG12V-expressing cells secreted to the culture me-
dium soluble factors that had pro-cancerous effects
that promoted tumor growth, as was previously indi-
cated by our in vitro analyses of CXCL8 (Figure 1).
CellsRas-G12V+TNFαCMRas-G12V+TNFα also gave rise to big-
ger tumors than CellsControlCMControl (groups 4 vs. 1),
but no significant difference was found when the
CellsRas-G12V+TNFαCMRas-G12V+TNFα group was com-
pared to CellsRas-G12V+TNFαCMControl (groups 4 vs. 3)
(Several of the mice in group 4 had bigger tumors, but
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These results suggest that the expression of RasG12V in
the cells has pushed the tumor-promoting potential to
its outmost values (in group 3), and thus it could not
have been promoted any further by CMRas-G12V+TNFα
(in group 4).
A different pattern was revealed when metastasis was
examined since highly pro-metastatic capacities were ob-
tained by the CellsRas-G12V+TNFαCMRas-G12V+TNFα group
compared to all other treatment combinations. Here, a
reliable criterion was tumor cell dissemination to LN ad-
jacent to mammary fat pad (see “Methods”). Using the
Maestro device in analyses of intact mice, we found that
CellsRas-G12V+TNFαCMRas-G12V+TNFα gave rise to signifi-
cantly higher metastatic yield than each of the other
three Cell-CM combinations. In mice inoculated by
CellsRas-G12V+TNFαCMRas-G12V+TNFα, the lag period until
dissemination of tumor cells to LN was shorter, and the
percentage of mice with LN metastases was higher
(83%) compared to all other Cell-CM combinations (12-
36%; Figure 6C).
Of note was the fact that increased LN dissemination
necessitated the expression of RasG12V in the cells as
well as supplementation of CM derived from cells ex-
pressing hyper-activated Ras and stimulated by TNFα
(=CMRasG12V+TNFα). Therefore, these results indicate
that in order to metastasize, the cells required the ex-
pression of RasG12V, but they also attest for the func-
tional importance of the cooperativity between TNFα
and Ras hyper-activation: Following joint activities of
TNFα and Ras hyper-activation, the cells released high
levels of tumor-promoting factors, which potentiated the
metastatic potential of the tumor cells and their dissem-
ination to LN.
Discussion
The multi-factorial nature of malignant diseases has led
researchers and clinicians to introduce novel therapeutic
approaches based on combination therapy. Deciphering
the molecular pathways involved in oncogenesis is es-
sential for the development of personalized therapies, as
is the identification of microenvironmental factors that
induce intrinsic alterations in cells that undergo malig-
nant transformation.
The findings presented in this study indicate that
oncogenic events, such as hyper-activation of the Ras
pathway, exacerbate the release of pro-malignancy che-
mokines (e.g., CXCL8 and CCL2) by MCF-7 human
breast tumor cells. Moreover, these processes are further
potentiated by inflammatory cytokines found in the
tumor microenvironment, such as TNFα and IL-1β. The
existence of such regulatory pathways is congruent with
the significantly higher levels of TNFα, IL-1β, CXCL8
and CCL2 expression in breast tumors, as compared tonormal breast cells [63], and with the ability of on-
cogenic RasG12V and TNFα (each alone) to up-regulate
CXCL8 expression (through NF-κB activation) in tumor
cells, as well as in other types of cells [33,34,36,64,65].
Our findings further demonstrate that TNFα trans-
forms WT-Ras into a tumor-promoting entity. In that
manner, the two components together induce the up-
regulation of CXCL8 (and possibly of other tumor-
promoting and angiogenic factors) and angiogenesis.
Therefore, being highly expressed in breast tumors,
TNFα may “bring the evil” out of WT-Ras and these two
components together may lead to intensified pro-
malignant effects that are deleterious in terms of angio-
genesis and tumor progression. It is important to
emphasize that following the activation of WT-Ras by
TNFα, the cooperative activity between the activated
form of WT-Ras and TNFα gives rise to CXCL8 up-
regulation in a manner similar to that achieved by the
constitutively active form of RasG12V. Thus, the powerful
ability of hyper-activated Ras + TNFα to promote metas-
tasis (Figure 6) strongly suggests that TNFα activation of
WT-Ras may lead to the dissemination of tumor cells.
The activation of WT-Ras by TNFα stimulation dem-
onstrates that inflammatory factors can activate onco-
genic pathways in breast tumor cells and promote
disease progression in breast cancer. These findings are
supported by several emerging studies in the field
[40,41], and if evidence to such processes will be ob-
tained by additional studies in breast cancer, they may
have important therapeutic implications (please see
below). From the mechanistic perspective, it is interest-
ing to indicate that the TNFα-induced activation process
of WT-Ras took hours to complete (Figure 3A), suggest-
ing that TNFα induces the release of RTK ligands by the
cells, which then activate the RTK-Ras pathway and lead
(via NF-κB and AP-1) to increased transcription and
protein expression of CXCL8. The involvement of RTK
activation in this process is supported by published stud-
ies showing that TNFα induces the transactivation of
ErbB2 in other cell systems (however, we note that those
investigations did not directly address Ras activation or
the effects of ErbB2-inducing activities on angiogenicity,
tumor growth and metastasis [40,41]). Thus, in our sys-
tem, it is possible that ErbB2 stimulation may be in-
volved in the activation of WT-Ras by TNFα-induced
signals. EGF may be one of the ligands that activate the
ErbB2 pathway, as suggested by our finding that EGF
induced CXCL8 expression in ErbB2-expressing cells
(Figure 2A). It is possible that the release of EGF and
many other RTK ligands (e.g., VEGF, bFGF, HGF) is
induced as a consequence of TNFα activation, leading
to RTK activation and then to cooperation in the release
of CXCL8 by the tumor cells. Obviously, a comprehen-
sive search based on protein arrays and neutralization
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teins that mediate the TNFα-induced WT-Ras activation
observed in our system and such work would constitute
an additional, full-scale research project. Nevertheless,
the actual evidence for such TNFα activity significantly
contributes to our understanding of the interactions be-
tween oncogenic events and microenvironmental pro-
cesses in breast cancer.
Furthermore, in the malignant cells the hyper-activated
RasG12V can act alone to promote the release of the an-
giogenic chemokines CXCL8 and CCL2. In contrast, in
non-transformed cells, the induction of CXCL8 and
CCL2 requires synergism between at least two onco-
genic modifications: RasG12V and the down-regulation
of p53. The latter pattern, evident in the non-transformed
cells, is congruent with the regulatory patterns ob-
served for other tumor-promoting characteristics in non-
transformed cells [66]. In contrast, the transformed tumor
cells already carried inherent alterations in their genetic/
signaling setup. Thus, the silencing of p53 may have been
replaced by modified activities of other protein/s in the
tumor cells that exhibited a fully established malignancy
phenotype. To identify candidate protein/s whose alter-
ation may cooperate with RasG12V, in-depth analyses of
the genetic/signaling setup of the tumor cells would need
to be carried out. That work would be appropriate for
future studies, but is beyond the scope of the present
investigation.
Our studies analyzing chemokine control by RasG12V ± p53
down-regulation have revealed similarities but also dif-
ferences in the regulatory mechanisms determining the
expression of CXCL8 and CCL2. As indicated above,
RasG12V alone induced the release of CXCL8 and of
CCL2. However, unlike CXCL8, CCL2 expression was
reduced when p53 was down-regulated in the context
of Ras hyper-activation. These findings agree with those
of recent studies showing that p53 was bound to CCL2
5′UTR and that the knockdown of human p53 has
led to strong negative regulation of CCL2 in macro-
phages [67,68]. Therefore, combining Ras hyper-activation
with down-regulation of p53 demonstrated the exist-
ence of different regulatory circuits for CXCL8 as com-
pared to CCL2.
Despite its ability to act alone in the tumor cells,
RasG12V had a relatively minor effect on pro-malignancy
activities in MCF-7 breast tumor cells (measured indir-
ectly in terms of CXCL8 release), as compared to the in-
flammatory cytokines (Figure 1B). Actually, it was the
joint activity of activated Ras and the inflammatory cyto-
kines that had the most powerful effects on CXCL8
release and metastasis. Our seminal finding in this re-
spect is that activities similar to those of RasG12V were
achieved using WT-Ras following its activation by TNFα
(Figure 2C). The strong metastasizing activities resultingout of the cooperation between hyper-activated Ras and
TNFα suggest that the activation of WT-Ras by TNFα
may give rise to more aggressive disease in breast cancer
patients expressing WT-Ras and high levels of TNFα.
Conclusions
In this study we have shown that TNFα rescued the
tumor-promoting potential of WT-Ras and have demon-
strated cooperativity between TNFα and activated Ras in
metastasis. The mechanisms revealed in this study and
in other supporting investigations suggest that oncogenic
events are promoted by inflammatory signals that reside
at the tumor microenvironment of breast tumors. Addi-
tional research in other breast tumor systems should be
taken in order to substantiate these mechanisms, as they
may have a significant impact on therapeutic approaches
for the treatment of cases of breast cancer in which the
tumors express high levels of TNFα and Ras is generally
not mutated. In light of such mechanisms, we may need
to consider the use of inhibitors of mutated (i.e., hyper-
activated) Ras in patients who do not have any apparent
constitutive activation of the oncogene due to its muta-
tion and also express high levels of TNFα, as is the case
for many breast cancer patients. Such inhibitors may in-
clude the farnesyl transferase inhibitors that are cur-
rently in clinical trials [2]. Furthermore, the interaction
observed between TNFα and WT-Ras suggests that the
therapeutic potential of Ras inhibitors would be en-
hanced if they were to be used together with the clinic-
ally available TNFα inhibitors, which have already been
investigated in the context of several other types of ma-
lignancies and have proven to be safe [6]. Thus, the
novel findings presented in our study have great clinical
relevance, as they emphasize the need to consider the
use of new therapeutic approaches in the treatment of
breast cancer.
Additional files
Additional file 1: Validation of efficiencies of p53shRNA or
GFP-RasG12V transfections. (A) MCF-7 cells were stably transfected to
express p53shRNA or control vector. p53 levels were determined by WB.
(B) MCF-7 cells were transiently transfected to express GFP-RasG12V or
GFP-control vector. Transfection efficiencies were determined by flow
cytometry of GFP-expressing cells. The activities of the Ras containing
vectors in the transfected cells were verified by Erk activation (data
not shown), and by quantitation of GTP-bound Ras levels, using RBD
pull-down assays as shown in Figure 3A of manuscript.
Additional file 2: RasG12V induces the expression of CCL2
independently of deregulated p53. MCF-7 cells were transfected to
express p53shRNA, RasG12V, RasG12V+p53shRNA or the appropriate control
vectors. CCL2 levels were determined at the protein level in cell superna-
tants by ELISA (A), and at the mRNA levels by qRT-PCR (B). **p<0.01,
***p<0.001 compared to control cells. NS = Not significant. In both
panels, a representative experiment of n≥3 is presented.
Additional file 3: ErbB2 and WT-Ras transfection yields, and Ras-related
parameters in cells transfected by RasG12V and by WT-Ras. (A) MCF-7
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http://www.biomedcentral.com/1471-2407/14/158cells were transiently transfected to express ErbB2 or control vector.
ErbB2 transfection efficiency was determined by qRT-PCR. ***p<0.001 for
differences between ErbB2-transfected, and control vector-transfected cells.
(B) MCF-7 cells were transiently transfected to express GFP-WT-Ras or GFP-
control vector. Transfection efficiencies were determined by flow cytometry
of GFP-expressing cells. The activities of the Ras containing vectors in the
transfected cells were verified by EGF stimulation followed by quantitation
of GTP-bound Ras levels, using RBD pull-down assays as shown in Figure 3A
of manuscript. (C) Determination of GTP-bound Ras levels. The Figure shows
the same WB results after brief film exposure and after longer film exposure,
in order to demonstrate that the lower band (presumably translationally
modified Ras) is expressed in WT-Ras-expressing cells, albeit in much lower
levels than in RasG12V-expressing cells. General transfection yields of
RasG12V were shown in Additional file 1B, and of WT-Ras in part B of
the current Figure. (D) The figure shows the relatively low (and unstable)
expression level of GTP-bound endogenous Ras (21 kDa) compared to
over-expressed GFP-tagged GTP-bound WT-Ras (48 kDa) obtained following
RBD assays (the results are from two different experiments: Exp. 1 - From
non-stimulated tumor cells; Exp. 2 - From cells stimulated by TNFα for 7
minutes, which are conditions in which Ras is not activated (see Figure 3A).
Additional file 4: Validating the inhibitory functions of PD98059 on
MAPK activation, indicated by levels of phosphorylated Erk. MCF-7
cells were transiently transfected to express WT-Ras and were not-
stimulated or stimulated by TNFα (50 ng/ml). This procedure was
performed in the absence or presence of the MEK inhibitor PD98059
(50 μM), or its solubilizer (DMSO, at similar dilution). PD98059 was added
to cell cultures 2 hr prior to stimulation of the cells by TNFα, and was
present in culture throughout the duration of stimulation. Erk activation
was determined by WB.
Additional file 5: IκBα levels in TNFα-stimulated WT-Ras expressing
cells, and p65 down-regulation by shRNAs to p65. (A) WT-Ras
expressing MCF-7 cells were not-stimulated or stimulated by TNFα
(50 ng/ml). Activation of the NF-κB pathway was analyzed by reduced
levels of IκBα (=NF-κB inhibitor), determined by WB. A representative
experiment of n=3 is presented. (B) Validation of the p65-reducing
activities of siRNAs to p65, determined by WB (Inhibition levels: 42%
and 62% inhibition for 25 nM and 35 nM siRNA to p65, respectively).
Reduction of p65 expression by siRNA targeting p65 was denoted in n=3.Abbreviations
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